Cerus (CERS) Stock Price, News & Analysis

Company Overview

Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The company offers INTERCEPT Blood Systems for platelets and plasma, which is designed to inactivate blood-borne pathogens in platelets and plasma donated for transfusion; INTERCEPT Blood System for red blood cells to inactivate blood-borne pathogens in red blood cells donated for transfusion; and INTERCEPT Blood System for Cryoprecipitation that uses its plasma system to produce pathogen reduced cryoprecipitated fibrinogen complex for the treatment and control of bleeding, including massive hemorrhage associated with fibrinogen deficiency, as well as pathogen reduced plasma, cryoprecipitate reduced. It sells platelet and plasma systems through its direct sales force and distributors in the United States, Europe, the Commonwealth of Independent States, the Middle East, Latin America, and internationally. Cerus Corporation was incorporated in 1991 and is headquartered in Concord, California.

Key Stats

• Today's Range: $1.68 to $1.77
• 50-Day Range: $1.52 to $2.03
• 52-Week Range: $1.38 to $2.59
• Volume: 1.08 million shs
• Average Volume: 1.27 million shs
• Market Capitalization: $313.86 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $3.63
• Consensus Rating: Moderate Buy

Cerus Stock Analysis - MarketRank™

Cerus scored higher than 62% of companies evaluated by MarketBeat, and ranked 418th out of 950 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Cerus has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on 3 buy ratings, 1 hold rating, and no sell ratings.

Amount of Analyst Coverage

Cerus has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Cerus are expected to grow in the coming year, from ($0.12) to ($0.08) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Cerus is -15.36, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Cerus is -15.36, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Cerus has a P/B Ratio of 5.83. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

3.56% of the outstanding shares of Cerus have been sold short.

Short Interest Ratio / Days to Cover

Cerus has a short interest ratio ("days to cover") of 4.4.

Change versus previous month

Short interest in Cerus has recently decreased by 4.34%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Cerus does not currently pay a dividend.

Dividend Growth

Cerus does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

3.56% of the outstanding shares of Cerus have been sold short.

Short Interest Ratio / Days to Cover

Cerus has a short interest ratio ("days to cover") of 4.4.

Change versus previous month

Short interest in Cerus has recently decreased by 4.34%, indicating that investor sentiment is improving.

News and Social Media

• Score: 3.3 / 5
• News Sentiment: 0.86

News Sentiment

Cerus has a news sentiment score of 0.86. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.75 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 4 news articles for Cerus this week, compared to 2 articles on an average week.

Search Interest

Only 1 people have searched for CERS on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

MarketBeat Follows

4 people have added Cerus to their MarketBeat watchlist in the last 30 days. This is an increase of 300% compared to the previous 30 days.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Cerus insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $35,600.00 in company stock.

Percentage Held by Insiders

Only 3.40% of the stock of Cerus is held by insiders.

Percentage Held by Institutions

78.37% of the stock of Cerus is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

CERS Stock Analysis - Frequently Asked Questions

How have CERS shares performed this year?

Cerus' stock was trading at $2.16 at the start of the year. Since then, CERS shares have decreased by 21.8% and is now trading at $1.69.
View the best growth stocks for 2024 here.

How were Cerus' earnings last quarter?

Cerus Co. (NASDAQ:CERS) posted its quarterly earnings results on Thursday, August, 1st. The biotechnology company reported ($0.03) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.04) by $0.01. The biotechnology company earned $45.08 million during the quarter, compared to the consensus estimate of $42.50 million. Cerus had a negative trailing twelve-month return on equity of 37.90% and a negative net margin of 11.19%.

Who are Cerus' major shareholders?

Cerus' top institutional shareholders include ARK Investment Management LLC (9.84%), Primecap Management Co. CA (4.60%), Wasatch Advisors LP (3.94%) and Sumitomo Mitsui Trust Group Inc. (3.80%). Insiders that own company stock include William Mariner Greenman, Vivek K Jayaraman, Kevin Dennis Green, Chrystal Jensen, Carol Moore, Richard J Benjamin, Chrystal Menard, Daniel N Swisher Jr, Ann Lucena, Hua Shan and Laurence M Corash.
View institutional ownership trends.

How do I buy shares of Cerus?

Shares of CERS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of Cerus own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Cerus investors own include American Water Works (AWK), Waste Connections (WCN), DiamondRock Hospitality (DRH), The RMR Group (RMR), Voyager Therapeutics (VYGR), AUO (AUOTY) and iShares Micro-Cap ETF (IWC).

Company Calendar

• Last Earnings: 8/01/2024
• Today: 12/18/2024
• Fiscal Year End: 12/31/2024

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Surgical & medical instruments
• Sub-Industry: Health Care Supplies
• Current Symbol: NASDAQ:CERS
• CUSIP: 15708510
• CIK: 1020214
• Web: www.cerus.com
• Phone: (925) 288-6000
• Fax: 925-288-6001
• Employees: 625
• Year Founded: 1991

Price Target and Rating

• Average Stock Price Target: $3.63
• High Stock Price Target: $5.00
• Low Stock Price Target: $2.50
• Potential Upside/Downside: +114.5%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.75
• Research Coverage: 4 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($0.11)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-37,490,000.00
• Net Margins: -11.19%
• Pretax Margin: -11.13%
• Return on Equity: -37.90%
• Return on Assets: -10.35%

Debt

• Debt-to-Equity Ratio: 1.19
• Current Ratio: 2.59
• Quick Ratio: 1.92

Sales & Book Value

• Annual Sales: $176.23 million
• Price / Sales: 1.78
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.29 per share
• Price / Book: 5.83

Miscellaneous

• Outstanding Shares: 185,715,000
• Free Float: 179,401,000
• Market Cap: $313.86 million
• Optionable: Optionable
• Beta: 1.24